Abstract: Steel for glass lining, comprising the following chemical elements in mass percent: C: 0.015-0.060%, Si: 0.01-0.50%, Mn: 0.20-1.5%, P: 0.005-0.10%, Al: 0.010-0.070%, Ti: 0.10-0.30%, and the balance of Fe and other inevitable impurities. The microstructure of the steel for glass lining is a ferrite or a combination of a ferrite and a cementite. In addition, also disclosed is a production method for steel for glass lining, comprising the steps of (1) smelting, refining, and continuous casting to obtain a slab; (2) heating, the heating temperature being 1050-1250° C.; (3) hot rolling, the final temperature of hot rolling being controlled to be 800-920° C.; (4) cooling; and (5) thermal treatment. The steel for glass lining has excellent machinability and low temperature toughness, and also has excellent lining performance.

Abstract: This invention relates to novel derivatives of camptothecin, and will, particularly to derivatives having a substitution at the C-7 position, or at one of the C-9, C-10, C-11 or C-12 positions, or to disubstituted derivatives having a first substitution at C-7 and a second at one of C-9, C-10, C-11 or C-12. The invention also includes methods of using the compounds as Topoisomerase I inhibitors to treat patients with cancer. The invention also includes pharmaceutical formulations which consist of the novel compounds in solution or suspension with one or more pharmaceutical excipients or dilutes.

Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.

Abstract: Novel compounds, formulations and methods of treating patients with cancer are provided for in this invention. The compounds are derivatives of camptothecin, and specifically relate to compounds having novel substitutions at the C-7 position of the camptothecin scaffold B-ring. The formula I compounds are highly lipophilic, lactone stable, do not require metabolic activation, and are potent antineoplastic compounds.